Introduction

Indonesia is an important market for pharmaceutical and healthcare companies seeking to expand across Southeast Asia. However, market entry involves more than preparing a product dossier. Companies must understand national registration requirements, demonstrate product quality, and maintain effective safety-monitoring systems after authorization.

The National Agency of Drug and Food Control, known as BPOM, oversees the regulation of medicines in Indonesia. Regulatory affairs and pharmacovigilance (PV) therefore need to operate as connected functions. Registration establishes the basis for market access, while ongoing safety and quality oversight helps protect patients and maintain compliance.

1. Understanding Indonesia's Regulatory Framework

BPOM is the main authority responsible for regulating medicines, including product registration and post-market supervision. Companies should identify the applicable product category and current regulatory pathway before preparing an application.

Indonesia's drug-registration framework has received updates, including BPOM Regulation No. 23 of 2025, which amended the existing criteria and procedures for drug registration. Regulatory teams should review the current consolidated requirements rather than relying exclusively on older checklists or historical submission practices.

A market-entry assessment should consider:

• Product classification and applicable registration pathway.
• Applicant and local authorization-holder responsibilities.
• Required quality, nonclinical, and clinical information.
• Administrative documentation and submission procedures.
• Applicable manufacturing and product-quality requirements.
• Post-authorization commitments and safety obligations.

Companies assessing Regulatory Services in Indonesia should consider how local registration activities connect with product strategy, dossier readiness, and continuing regulatory responsibilities.

2. Preparing Pharmaceutical Registration Dossiers

A registration dossier must present a consistent account of a medicine's quality, safety, and efficacy. Gaps between technical documents, proposed product information, and administrative records can create questions during regulatory review.

Build a submission-ready dossier

Before filing, regulatory and technical teams should confirm that the application reflects the latest available evidence and applicable BPOM requirements.

Key preparation activities include:

• Confirming the correct application category and supporting-document list.
• Reviewing active pharmaceutical ingredients and finished-product information.
• Checking manufacturing, control, and stability data for consistency.
• Verifying clinical and nonclinical evidence where applicable.
• Reviewing proposed labeling and product information.
• Establishing document version control and a formal quality check.

A clear dossier structure also helps organizations respond efficiently to questions from the authority. Teams should maintain traceability between source documents, dossier sections, and any commitments made during the review process.

3. Managing Pharmacovigilance Obligations

Pharmacovigilance is a continuing responsibility for companies that hold marketing authorizations. It includes collecting and evaluating safety information, identifying potential risks, and communicating relevant findings to the regulator and healthcare stakeholders.

A significant recent development is BPOM Regulation No. 4 of 2026 on the Implementation of Pharmacovigilance. It took effect on 26 February 2026 and replaced BPOM Regulation No. 15 of 2022. Companies should assess the new requirements and applicable transition arrangements when reviewing their PV systems.

Establish an effective safety system

A practical PV framework should include:

• Defined responsibilities for the marketing authorization holder and service providers.
• Procedures for receiving, documenting, and assessing adverse event reports.
• Processes for identifying and escalating serious or emerging safety concerns.
• Applicable periodic post-marketing safety reporting and risk-management activities.
• Training, oversight, and records that support regulatory inspection.

Under the 2026 framework, reporting obligations cover relevant safety information and may include individual case reports, periodic safety reports, risk-management plan implementation, and safety signals. Specific deadlines depend on the report type and circumstances. Companies should consult the regulation and its annexes rather than assume one timeline applies to every case.

Organizations reviewing Pharmacovigilance Services in Indonesia should assess local expertise, case-processing procedures, escalation pathways, and the ability to meet current BPOM requirements.

4. Maintaining CMC and Product Quality Compliance

Chemistry, Manufacturing and Controls (CMC) information is central to demonstrating that a medicine can be consistently manufactured to the required quality standards. It covers the product's composition, manufacturing process, specifications, analytical controls, and stability.

Regulatory and quality teams should work together to ensure that CMC information remains aligned across the dossier and the current manufacturing process.

Important considerations include:

• Approved specifications and analytical methods.
• Manufacturing-site and process information.
• Stability data and shelf-life justification.
• Supplier and material controls.
• Change assessment and supporting comparability evidence.

Well-governed CMC Regulatory Services can help organizations structure technical documentation and assess regulatory implications of manufacturing or quality changes.

5. Coordinating Post-Approval Changes

Authorization is not the end of regulatory work. Changes to manufacturing sites, specifications, processes, product information, or other approved details may require regulatory assessment and, depending on the change, prior approval or notification.

A controlled lifecycle process should:

• Identify proposed changes early.
• Assess quality, safety, and regulatory impact.
• Determine the applicable submission category.
• Maintain evidence and approval records.
• Track implementation against regulatory conditions.

Effective Post Approval Life Cycle Management helps teams coordinate variations, renewals, commitments, and changes without losing oversight of the approved product status.

Conclusion

Regulatory success in Indonesia depends on an integrated approach to registration, product quality, pharmacovigilance, and post-approval oversight. Companies that maintain current regulatory intelligence, clear responsibilities, and reliable documentation are better equipped to manage changing requirements and protect patients.

Because BPOM requirements evolve, organizations should verify the latest regulations and product-specific guidance before submitting applications or making compliance decisions.

Why Choose DDReg as your Consulting Partner

Teams planning or reviewing their Indonesian regulatory strategy can explore Life Science Consulting Services for broader regulatory context, Regulatory Intelligence Tools to monitor regulatory developments, and Regulatory Affairs Lifecycle Management when coordinating ongoing product obligations.